LEADER program results for 2009: An activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 8, 2011, Pages 3684-3690

  Farrell, David J ^a   Mendes, Rodrigo E ^a   Ross, James E ^a   Sader, Helio S ^a   Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; PENICILLIN G; RNA 23S; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; ENTEROCOCCUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS CAPITIS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS; HUMANS; INTERSPERSED REPETITIVE SEQUENCES; LONGITUDINAL STUDIES; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, RIBOSOMAL, 23S; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; VIRIDANS STREPTOCOCCI;

EID: 79960332126     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01729-10     Document Type: Article

References (34)

1. Arias, C. A., et al. 2008. Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase. J. Clin. Microbiol. 46:892-896.
2. Bonilla, H., et al. 2010. Multicity outbreak of linezolid-resistant Staphylococcus epidermidis associated with clonal spread of a cfr-containing strain. Clin. Infect. Dis. 51:796-800.
3. Brickner, S. J. 1996. Oxazolidinone antibacterial agents. Curr. Pharm. Des. 2:175-194.
4. Chen, D. K., A. McGeer, J. C. de Azavedo, and D. E. Low. 1999. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N. Engl. J. Med. 341:233-239.
5. CLSI. 2009. M02-A10. Performance standards for antimicrobial disk susceptibility tests; approved standard, 10th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
6. CLSI. 2009. M07-A8. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
7. CLSI. 2010. M100-S20-U. Performance standards for antimicrobial susceptibility testing; 20th informational supplement (June 2010 update). Clinical and Laboratory Standards Institute, Wayne, PA.
8. Diekema, D. J., and R. N. Jones. 2001. Oxazolidinone antibiotics. Lancet 358:1975-1982.
9. Draghi, D. C., D. J. Sheehan, P. Hogan, and D. F. Sahm. 2005. In vitro activity of linezolid against key gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program. Antimicrob. Agents Chemother. 49:5024-5032.
10. Endimiani, A., et al. 2011. Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio. Antimicrob. Agents Chemother. 55:1684-1692.
11. Farrell, D. J., R. E. Mendes, J. E. Ross, and R. N. Jones. 2009. Linezolid surveillance program results for 2008 (LEADER Program for 2008). Diagn. Microbiol. Infect. Dis. 65:392-403.
12. Gomez-Gil, R., et al. 2009. Nosocomial outbreak of linezolid-resistant Enterococcus faecalis infection in a tertiary care hospital. Diagn. Microbiol. Infect. Dis. 65:175-179.
13. Gonzales, R. D., et al. 2001. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357:1179.
14. Jenkins, S. G., and D. J. Farrell. 2009. Increase in pneumococcal macrolide resistance, United States. Emerg. Infect. Dis. 15:1260-1264.
15. Jones, R. N., T. R. Fritsche, H. S. Sader, and J. E. Ross. 2007. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagn. Microbiol. Infect. Dis. 59:309-317.
16. Jones, R. N., S. Kohno, Y. Ono, J. E. Ross, and K. Yanagihara. 2009. ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries. Diagn. Microbiol. Infect. Dis. 64:191-201.
17. Jones, R. N., J. E. Ross, M. Castanheira, and R. E. Mendes. 2008. United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagn. Microbiol. Infect. Dis. 62:416-426.
18. Jones, R. N., H. S. Sader, G. J. Moet, and D. J. Farrell. 2010. Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998-2009). Diagn. Microbiol. Infect. Dis. 68:334-336.
19. Kainer, M. A., et al. 2007. Response to emerging infection leading to outbreak of linezolid-resistant enterococci. Emerg. Infect. Dis. 13:1024-1030.
20. Kelly, S., J. Collins, M. Davin, C. Gowing, and P. G. Murphy. 2006. Linezolid resistance in coagulase-negative staphylococci. J. Antimicrob. Chemother. 58:898-900.
21. Long, K. S., J. Poehlsgaard, C. Kehrenberg, S. Schwarz, and B. Vester. 2006. The cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob. Agents Chemother. 50:2500-2505.
22. Mendes, R. E., et al. 2008. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob. Agents Chemother. 52:2244-2246.
23. Mutnick, A. H., V. Enne, and R. N. Jones. 2003. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program. Ann. Pharmacother. 37:769-774.
24. Sanchez-Gomez, J. C., et al. 2006. Linezolid-resistant Enterococcus faecalis: first report in Spain. J. Chemother. 18:440-442. (Pubitemid 44450030)
25. Shinabarger, D. 1999. Mechanism of action of the oxazolidinone antibacterial agents. Expert Opin. Invest. Drugs 8:1195-1202.
26. Shorr, A. F., M. J. Kunkel, and M. Kollef. 2005. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J. Antimicrob. Chemother. 56:923-929.
27. Stevens, D. L., et al. 2002. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 34: 1481-1490. (Pubitemid 34553708)
28. Toh, S. M., et al. 2007. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol. Microbiol. 64:1506-1514.
29. Tsiodras, S., et al. 2001. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358:207-208.
30. Weigelt, J., et al. 2005. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 49: 2260-2266.
31. Wilson, P., et al. 2003. Linezolid resistance in clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 51:186-188.
32. Wunderink, R. G., S. K. Cammarata, T. H. Oliphant, and M. H. Kollef. 2003. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin. Ther. 25:980-992.
33. Wunderink, R. G., J. Rello, S. K. Cammarata, R. V. Croos-Dabrera, and M. H. Kollef. 2003. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124:1789-1797.
34. Zurenko, G. E., et al. 1996. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob. Agents Chemother. 40:839-845.